Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Varsha Gandhi, PhD, on Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Oct
08
Today In Oncology
Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia
Predicting Future Breast Cancer Outcomes Efficacy of a Polygenic Risk Score
Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC
Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia
Contemporary Management of Chronic Myeloid Leukemia, According to Hagop M. Kantarjian, MD, FASCO
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo